Τίτλος:
Immunotherapy for cholangiocarcinoma: A 2021 update
Γλώσσες Τεκμηρίου:
Αγγλικά
Περίληψη:
Cholangiocarcinoma (CCA) is a rare malignancy with generally dismal prognosis. Immunotherapy has revolutionized the management of cancer patients during the last decade, offering durable responses with an acceptable safety profile, but there are still no significant advances regarding CCA. Novel immunotherapeutic methods, such as cancer vaccines, oncolytic viruses, adoptive cell therapy and combinations of immune checkpoint inhibitors with other agents are currently under investigation and may improve prognosis. Efforts to find robust biomarkers for response are also ongoing. In this review, we discuss the rationale for the use of immunotherapy in CCA and available clinical data. Ongoing trials will also be presented, as well as key findings from each study. © 2021 Future Medicine Ltd.. All rights reserved.
Συγγραφείς:
Charalampakis, N.
Papageorgiou, G.
Tsakatikas, S.
Fioretzaki, R.
Kole, C.
Kykalos, S.
Tolia, M.
Schizas, D.
Περιοδικό:
Journal of Immunotherapy
Εκδότης:
Future Medicine Ltd
Λέξεις-κλειδιά:
bile duct cancer; bile duct carcinoma; human; immunology; immunotherapy; procedures, Bile Duct Neoplasms; Cholangiocarcinoma; Humans; Immunotherapy
DOI:
10.2217/imt-2021-0126
